133 related articles for article (PubMed ID: 11511159)
1. Hepatocellular injury in a patient receiving pioglitazone.
Maeda K
Ann Intern Med; 2001 Aug; 135(4):306. PubMed ID: 11511159
[No Abstract] [Full Text] [Related]
2. [A case of drug induced liver injury related pioglitazone].
Hisamochi A; Kumashiro R; Koga Y; Tanaka E; Ide T; Hino T; Murashima S; Ogata K; Kuwahara R; Koga H; Shishido S; Ueno T; Sata M; Eguchi T
Nihon Shokakibyo Gakkai Zasshi; 2003 Mar; 100(3):333-6. PubMed ID: 12696176
[No Abstract] [Full Text] [Related]
3. Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Ann Intern Med; 2002 Mar; 136(6):I65. PubMed ID: 11900516
[No Abstract] [Full Text] [Related]
4. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
May LD; Lefkowitch JH; Kram MT; Rubin DE
Ann Intern Med; 2002 Mar; 136(6):449-52. PubMed ID: 11900497
[TBL] [Abstract][Full Text] [Related]
5. "Did this drug cause my patient's hepatitis?" and related questions.
Nierenberg DW
Ann Intern Med; 2002 Mar; 136(6):480-3. PubMed ID: 11900502
[No Abstract] [Full Text] [Related]
6. Late-onset troglitazone-induced hepatic dysfunction.
Bell DS; Ovalle F
Diabetes Care; 2000 Jan; 23(1):128-9. PubMed ID: 10857986
[No Abstract] [Full Text] [Related]
7. Severe but reversible hepatitis induced by troglitazone.
Schiano T; Dolehide K; Hart J; Baker AL
Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
[No Abstract] [Full Text] [Related]
8. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
9. Severe but reversible cholestatic liver injury after pioglitazone therapy.
Pinto AG; Cummings OW; Chalasani N
Ann Intern Med; 2002 Nov; 137(10):857. PubMed ID: 12435231
[No Abstract] [Full Text] [Related]
10. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
11. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
12. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Al-Salman J; Arjomand H; Kemp DG; Mittal M
Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone-associated fulminant hepatic failure.
Chase MP; Yarze JC
Am J Gastroenterol; 2002 Feb; 97(2):502-3. PubMed ID: 11866308
[No Abstract] [Full Text] [Related]
14. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
15. What caused this patient's sudden liver dysfunction?
Porterfield LM
RN; 2001 Mar; 64(3):98. PubMed ID: 11288655
[No Abstract] [Full Text] [Related]
16. Angioneurotic edema as a side effect of pioglitazone.
Shadid S; Jensen MD
Diabetes Care; 2002 Feb; 25(2):405. PubMed ID: 11815525
[No Abstract] [Full Text] [Related]
17. Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?
Nagai Y; Abe T; Nomura G
Diabetes Care; 2001 Feb; 24(2):408-9. PubMed ID: 11213903
[No Abstract] [Full Text] [Related]
18. Substituting for troglitazone (Rezulin).
Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176
[No Abstract] [Full Text] [Related]
19. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
20. Fatal hepatotoxicity associated with troglitazone.
Vella A; de Groen PC; Dinneen SF
Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
